Gene: GRIA2

2891
GLUR2|GLURB|GluA2|GluR-K2|HBGR2
glutamate ionotropic receptor AMPA type subunit 2
protein-coding
4q32.1
Ensembl:ENSG00000120251 MIM:138247 Vega:OTTHUMG00000133836 UniprotKB:P42262
NC_000004.12
PubMed
0   ANCO-SNPs
ND|AD
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.673e-2 (AD)  6.675e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CHL10.97
ATP2B10.968
SFXN10.964
DZIP30.961
PPFIA20.961
CNKSR20.958
SCN2A0.958
CDK5R10.958
NRXN10.957
ARHGEF90.957

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.562
TFPI2-0.511
CSAG1-0.508
OR4F29-0.507
FZD10-0.455
CNN2-0.452
RAI14-0.449
KCNJ15-0.436
HEY2-0.434
FOLR3-0.433

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00142Glutamic AcidSmall Molecule56-86-0Approved|NutraceuticalTarget
DB00237ButabarbitalSmall Molecule125-40-6Approved|IllicitTarget
DB00241ButalbitalSmall Molecule77-26-9Approved|IllicitTarget
DB00306TalbutalSmall Molecule115-44-6Approved|IllicitTarget
DB00312PentobarbitalSmall Molecule76-74-4Approved|InvestigationalTarget
DB00418SecobarbitalSmall Molecule76-73-3ApprovedTarget
DB00463MetharbitalSmall Molecule50-11-3WithdrawnTarget
DB00599ThiopentalSmall Molecule76-75-5ApprovedTarget
DB00794PrimidoneSmall Molecule125-33-7ApprovedTarget
DB00849MethylphenobarbitalSmall Molecule115-38-8ApprovedTarget
DB00898EthanolSmall Molecule64-17-5ApprovedTarget
DB01174PhenobarbitalSmall Molecule50-06-6Approved|InvestigationalTarget
DB01346Quinidine barbiturateSmall Molecule-ApprovedTarget
DB01351AmobarbitalSmall Molecule57-43-2Approved|IllicitTarget
DB01352AprobarbitalSmall Molecule77-02-1Approved|IllicitTarget
DB01353ButethalSmall Molecule77-28-1Approved|IllicitTarget
DB01354HeptabarbitalSmall Molecule509-86-4ApprovedTarget
DB01355HexobarbitalSmall Molecule56-29-1ApprovedTarget
DB01483BarbitalSmall Molecule57-44-3IllicitTarget
DB01496Barbituric acid derivativeSmall MoleculeExperimental|IllicitTarget
DB01664(S)-Des-Me-AmpaSmall MoleculeExperimentalTarget
DB02057(S)-AMPASmall Molecule83643-88-3ExperimentalTarget
DB023472-Amino-3-(5-Tert-Butyl-3-(Phosphonomethoxy)-4-Isoxazolyl)Propionic AcidSmall MoleculeExperimentalTarget
DB02818Iodo-WillardiineSmall MoleculeExperimentalTarget
DB02966Fluoro-WillardiineSmall MoleculeExperimentalTarget
DB02999QuisqualateSmall MoleculeExperimentalTarget
DB03240(S)-2-Amino-3-(1,3,5,7-Pentahydro-2,4-Dioxo-Cyclopenta[E]Pyrimidin-1-Yl) Proionic AcidSmall MoleculeExperimentalTarget
DB03319(S)-ATPASmall MoleculeExperimentalTarget
DB03759FG-9041Small Molecule2379-57-9ExperimentalTarget
DB04000Bromo-WillardiineSmall MoleculeExperimentalTarget
DB04129WillardiineSmall MoleculeExperimentalTarget
DB041522-Amino-3-(3-Hydroxy-7,8-Dihydro-6h-Cyclohepta[D]-4-Isoxazolyl)Propionic AcidSmall MoleculeExperimentalTarget
DB04599AniracetamSmall Molecule72432-10-1ExperimentalTarget
DB04798THIO-ATPASmall MoleculeExperimentalTarget
DB04982TalampanelSmall Molecule161832-65-1InvestigationalTarget
DB05047CX717Small Molecule-Illicit|InvestigationalTarget
DB07455N,N'-[biphenyl-4,4'-diyldi(2R)propane-2,1-diyl]dimethanesulfonamideSmall MoleculeExperimentalTarget
DB075982,3,6A,7,8,9-HEXAHYDRO-11H-[1,4]DIOXINO[2,3-G]PYRROLO[2,1-B][1,3]BENZOXAZIN-11-ONESmall MoleculeExperimentalTarget
DB08303(3S)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxideSmall MoleculeExperimentalTarget
DB08304(3R)-3-cyclopentyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxideSmall MoleculeExperimentalTarget
DB08305(3R)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxideSmall MoleculeExperimentalTarget
DB13146Fluciclovine (18F)Small Molecule222727-39-1ApprovedTarget
ID Drug Name Action PubMed
C0675061-naphthylacetylspermineGRIA2 protein results in decreased susceptibility to 1-naphthylacetylspermine28725974
C4748292-amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid2-amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid binds to and results in increased activity of [GRIA1 protein binds to GRIA2 protein]21923187
C1110462-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid binds to GRIA2 protein21923187
C4723653-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine"3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine inhibits the reaction [Methamphetamine results in increased expression of GRIA2 protein]"23711322
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIA2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIA2 mRNA"27188386
C0233664-bromohomoibotenic acid4-bromohomoibotenic acid binds to and results in increased activity of [GRIA1 protein binds to GRIA2 protein]21923187
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIA2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIA2 mRNA"27188386
C0005950156,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine"6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine results in increased expression of GRIA2 mRNA"28073004
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA25607892
D020106AcrylamideAcrylamide results in decreased expression of GRIA2 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of GRIA2 mRNA23630614
D018350alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acidalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid inhibits the reaction [Propofol results in increased expression of GRIA2 protein]28663055
D000643Ammonium ChlorideAmmonium Chloride affects the expression of GRIA2 mRNA16483693
D000661AmphetamineAmphetamine affects the expression of GRIA2 mRNA alternative form15784965
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA25607892
C025657arsenic acidarsenic acid analog results in decreased expression of GRIA2 mRNA19761793
C006632arsenic trioxidearsenic trioxide results in decreased expression of GRIA2 mRNA24831965
C015001arsenitearsenite results in increased methylation of GRIA2 promoter23974009
D001565BenzoatesBenzoates analog binds to and results in decreased activity of GRIA2 protein14667236
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of GRIA2 mRNA28412278
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of GRIA2 protein28412278
D001564Benzo(a)pyreneSNAP25 protein affects the reaction [Benzo(a)pyrene results in decreased expression of GRIA2 mRNA]28412278
D001564Benzo(a)pyreneSNAP25 protein affects the reaction [Benzo(a)pyrene results in decreased expression of GRIA2 protein]28412278
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of GRIA2 protein28412278
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased localization of GRIA2 protein19674091
D004958Estradiol[Estradiol co-treated with Progesterone] results in increased expression of GRIA2 mRNA22154832
D004958EstradiolEstradiol results in increased expression of GRIA2 mRNA22154832
D001640BicucullineBicuculline results in decreased expression of GRIA2 protein22262897
D001640BicucullineMECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein]22262897
D001640BicucullineBicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]22262897
D001640BicucullineBicuculline results in decreased expression of and results in decreased localization of GRIA2 protein19674091
D001640BicucullineBicuculline results in decreased expression of GRIA2 mRNA22262897
D001640BicucullineBicuculline results in decreased expression of GRIA2 protein22262897
D001640BicucullineMECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein]22262897
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of GRIA2 mRNA22504913|2518105
D001761BleomycinBleomycin results in decreased expression of GRIA2 mRNA15808516
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA25607892
D002118CalciumCalcium promotes the reaction [PICK1 protein binds to GRIA2 protein]28404816
D002235CarbofuranCarbofuran results in decreased expression of GRIA2 protein28725974
D000068579CelecoxibCelecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA2 mRNA]21589914
D004390ChlorpyrifosChlorpyrifos results in decreased expression of GRIA2 mRNA18668222|1944049
C466858ciguatoxin 3Cciguatoxin 3C results in decreased expression of GRIA2 protein25945544
C466858ciguatoxin 3CTetrodotoxin inhibits the reaction [ciguatoxin 3C results in decreased expression of GRIA2 protein]25945544
D003024ClozapineClozapine results in increased expression of GRIA2 mRNA17141476
D003042CocaineCocaine results in increased expression of GRIA2 protein16363995
D003042CocaineCocaine results in increased expression of GRIA2 protein16363995
D003042CocaineCocaine results in increased expression of GRIA2 mRNA9886066
D003042CocaineCocaine affects the expression of GRIA2 mRNA12511956|2018794
D003042CocaineCocaine affects the expression of GRIA2 protein12511956|1278707
D003042CocaineCocaine results in increased phosphorylation of and affects the localization of GRIA2 protein18945913
D003042CocaineGRIA2 results in decreased susceptibility to Cocaine12511956
D003471CuprizoneCuprizone results in decreased expression of GRIA2 mRNA26577399
D0187506-Cyano-7-nitroquinoxaline-2,3-dione"6-Cyano-7-nitroquinoxaline-2,3-dione results in increased expression of and results in increased localization of GRIA2 protein"19674091
D003561CytarabineCytarabine results in increased expression of GRIA2 mRNA21198554
D003976DiazinonDiazinon results in decreased expression of GRIA2 mRNA17452286|1944049
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA25607892
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA25607892
D004026DieldrinDieldrin results in decreased expression of GRIA2 mRNA19440498
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA25607892
D004054DiethylstilbestrolDiethylstilbestrol results in decreased expression of GRIA2 mRNA22504913
D004227Dithionite[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein27238724
D004227DithioniteGenistein inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein]27238724
D004298DopamineDopamine results in increased localization of GRIA2 protein19674091
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA25607892
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA25607892
D000431EthanolEthanol affects the expression of GRIA2 mRNA11772933
D000431EthanolEthanol results in decreased expression of GRIA2 mRNA20655511
D000431Ethanol"N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid inhibits the reaction [Ethanol results in decreased expression of GRIA2 mRNA]"20655511
C017690fenvaleratefenvalerate results in decreased expression of GRIA2 protein26961610
D005411Flame RetardantsFlame Retardants results in increased expression of GRIA2 mRNA27219277
D005473FluoxetineFluoxetine results in increased expression of GRIA2 protein20417256
D019833GenisteinGenistein inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein]27238724
D019833GenisteinGenistein results in decreased expression of GRIA2 mRNA22504913
D005947Glucose[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein27238724
D005947GlucoseGenistein inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein]27238724
D055768Halogenated Diphenyl EthersHalogenated Diphenyl Ethers results in increased expression of GRIA2 mRNA27219277
D006220HaloperidolHaloperidol results in increased expression of GRIA2 mRNA17141476
D007608Kainic AcidCelecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA2 mRNA]21589914
D007608Kainic AcidGRIA2 protein affects the susceptibility to Kainic Acid10551584
D007608Kainic AcidKainic Acid results in decreased expression of GRIA2 mRNA21589914|2409846
D007608Kainic AcidKainic Acid results in increased methylation of GRIA2 gene24098468
D007608Kainic AcidRG108 inhibits the reaction [Kainic Acid results in increased methylation of GRIA2 gene]24098468
D007608Kainic AcidKainic Acid binds to and results in increased activity of GRIA2 protein11812690
D007608Kainic AcidKainic Acid results in decreased expression of GRIA2 mRNA7529610
D007608Kainic AcidKainic Acid results in increased methylation of GRIA2 gene24098468
D007608Kainic AcidUrethane inhibits the reaction [Kainic Acid binds to and results in increased activity of GRIA2 protein]11812690
D007657Ketone BodiesKetone Bodies results in increased expression of GRIA2 mRNA16807920
C067713lactacystinlactacystin results in increased localization of GRIA2 protein19674091
D007854LeadBDNF protein inhibits the reaction [Lead results in decreased expression of GRIA2 protein]23719929
D007854LeadLead results in decreased expression of GRIA2 protein23719929
C008261lead acetatelead acetate results in decreased expression of GRIA2 mRNA24260418
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA25607892
D008094Lithium[Lithium co-treated with Pilocarpine] results in increased expression of GRIA2 mRNA16819974
D008094LithiumLithium results in decreased expression of GRIA2 protein18171924
D008694Methamphetamine"3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine inhibits the reaction [Methamphetamine results in increased expression of GRIA2 protein]"23711322
D008694MethamphetamineMethamphetamine results in increased expression of GRIA2 mRNA18419818
D008694MethamphetamineMethamphetamine results in increased expression of GRIA2 protein23711322
D008731MethoxychlorMethoxychlor results in decreased expression of GRIA2 protein26961610
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of GRIA2 mRNA"19285098
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in decreased expression of GRIA2 mRNA24810058
D009020MorphineMorphine results in decreased expression of GRIA2 protein23711322
C479831N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea"N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea affects the localization of GRIA2 protein"20534517
D009532NickelNickel affects the expression of GRIA2 mRNA14575637
D009532NickelNickel results in decreased expression of GRIA2 mRNA24768652|2558310
D009532Nickeltrichostatin A inhibits the reaction [Nickel affects the expression of GRIA2 mRNA]14575637
C520612N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid"N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid inhibits the reaction [Ethanol results in decreased expression of GRIA2 mRNA]"20655511
C025589ochratoxin Aochratoxin A results in increased expression of GRIA2 mRNA27346841
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA25607892
D016627OxidopamineOxidopamine results in decreased expression of GRIA2 mRNA11290405
C076029olanzapineolanzapine results in increased expression of GRIA2 mRNA11526992
D010269ParaquatParaquat results in decreased expression of GRIA2 protein24521700
D010406PenicillinsPenicillins results in decreased expression of GRIA2 mRNA19446251
D010424PentobarbitalGRIA2 protein affects the susceptibility to Pentobarbital10551584
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in decreased expression of GRIA2 mRNA27155986
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in decreased expression of GRIA2 protein27155986
D010634PhenobarbitalGRIA2 protein affects the susceptibility to Phenobarbital10551584
D010862Pilocarpine[Lithium co-treated with Pilocarpine] results in increased expression of GRIA2 mRNA16819974
D010862PilocarpinePilocarpine results in decreased expression of GRIA2 mRNA19222700
D010862PilocarpinePilocarpine results in increased expression of GRIA2 3' UTR alternative form19222700
D010862PilocarpinePilocarpine results in increased expression of GRIA2 protein15857427
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA25607892
D011374Progesterone[Estradiol co-treated with Progesterone] results in increased expression of GRIA2 mRNA22154832
D015742Propofolalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid inhibits the reaction [Propofol results in increased expression of GRIA2 protein]28663055
D015742PropofolPropofol results in increased expression of GRIA2 protein28663055
D011441PropylthiouracilPropylthiouracil results in increased expression of GRIA2 mRNA24780913
D0014983-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester"3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of GRIA2 protein"28194001
C503639RG108RG108 inhibits the reaction [Kainic Acid results in increased methylation of GRIA2 gene]24098468
D012643SeleniumSelenium results in decreased expression of GRIA2 mRNA19244175
D012715Sesame OilSesame Oil results in increased expression of GRIA2 mRNA29191790
D012834SilverSilver results in decreased expression of GRIA2 mRNA27131904
C017947sodium arseniteGRIA2 protein results in decreased susceptibility to sodium arsenite23694735
C017947sodium arsenitesodium arsenite results in decreased expression of GRIA2 protein29204679
D013458Sulfur DioxideSulfur Dioxide results in decreased expression of GRIA2 mRNA25534910
D013605T-2 ToxinT-2 Toxin results in decreased expression of GRIA2 mRNA26314264
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of GRIA2 mRNA16922920
D013779TetrodotoxinTetrodotoxin inhibits the reaction [ciguatoxin 3C results in decreased expression of GRIA2 protein]25945544
D013779TetrodotoxinTetrodotoxin results in increased expression of GRIA2 protein25945544
D013779TetrodotoxinTetrodotoxin results in increased localization of GRIA2 protein19674091
D013874ThiopentalGRIA2 protein affects the susceptibility to Thiopental10551584
D024505TocopherolsTocopherols results in increased expression of GRIA2 mRNA17654050
D014050TolueneToluene affects the expression of GRIA2 mRNA21827849
D014212TretinoinTretinoin results in decreased expression of GRIA2 mRNA16604517
C011559tributyltintributyltin results in increased expression of GRIA2 mRNA29191790
C011559tributyltintributyltin results in decreased expression of GRIA2 mRNA19591855
C011559tributyltintributyltin results in decreased expression of GRIA2 protein19591855
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIA2 mRNA"27188386
C012589trichostatin Atrichostatin A inhibits the reaction [Nickel affects the expression of GRIA2 mRNA]14575637
C012589trichostatin Atrichostatin A results in increased expression of GRIA2 mRNA24935251|2627250
D014302Trinitrobenzenesulfonic AcidTrinitrobenzenesulfonic Acid results in increased expression of GRIA2 mRNA23537331
D014520UrethaneUrethane inhibits the reaction [Kainic Acid binds to and results in increased activity of GRIA2 protein]11812690
D014635Valproic AcidValproic Acid affects the expression of GRIA2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of GRIA2 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in decreased expression of GRIA2 protein18171924
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of GRIA2 gene25560391
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA25607892
C025643vinclozolinvinclozolin affects the expression of GRIA2 mRNA19015723
D014810Vitamin EVitamin E results in decreased expression of GRIA2 mRNA19244175
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIA2 mRNA"27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001540amyloid-beta binding-ISS-  
GO:0001540amyloid-beta binding-NAS20032460  
GO:0004970ionotropic glutamate receptor activity-IDA20614889  
GO:0004971AMPA glutamate receptor activity-IBA21873635  
GO:0004971AMPA glutamate receptor activity-ISS-  
GO:0004971AMPA glutamate receptor activitycontributes_toNAS20032460  
GO:0005231excitatory extracellular ligand-gated ion channel activity-TAS-  
GO:0005234extracellularly glutamate-gated ion channel activity-IEA-  
GO:0005515protein binding-IPI12130635  16724110  20018661  
GO ID GO Term Qualifier Evidence PubMed
GO:0007165signal transduction-TAS8003671  
GO:0007268chemical synaptic transmission-TAS8003671  
GO:0034220ion transmembrane transport-IEA-  
GO:0035235ionotropic glutamate receptor signaling pathway-IDA20614889  
GO:0035249synaptic transmission, glutamatergic-TAS21221849  
GO:0060079excitatory postsynaptic potential-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005789endoplasmic reticulum membrane-IEA-  
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-ISS-  
GO:0009897external side of plasma membrane-TAS21221849  
GO:0030054cell junction-IEA-  
GO:0030425dendrite-ISS-  
GO:0030666endocytic vesicle membrane-TAS-  
GO:0032281AMPA glutamate receptor complex-IBA21873635  
GO:0032281AMPA glutamate receptor complex-ISS-  
GO:0043197dendritic spine-NAS20032460  
GO:0045211postsynaptic membrane-IEA-  
GO:0060076excitatory synapse-NAS20032460  
GO:0098794postsynapse-TAS21221849  
GO:0098843postsynaptic endocytic zone-NAS20032460  
KEGG ID KEGG Term
hsa04080Neuroactive ligand-receptor interaction
hsa04720Long-term potentiation
hsa04730Long-term depression
hsa05014Amyotrophic lateral sclerosis (ALS)
Reactome ID Reactome Term Evidence
R-HSA-112314Neurotransmitter receptors and postsynaptic signal transmissionTAS
R-HSA-112315Transmission across Chemical SynapsesTAS
R-HSA-112316Neuronal SystemTAS
R-HSA-399710Activation of AMPA receptorsTAS
R-HSA-399719Trafficking of AMPA receptorsTAS
R-HSA-399721Glutamate binding, activation of AMPA receptors and synaptic plasticityTAS
R-HSA-416993Trafficking of GluR2-containing AMPA receptorsTAS
R-HSA-438066Unblocking of NMDA receptor, glutamate binding and activationTAS
R-HSA-442755Activation of NMDA receptor and postsynaptic eventsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
27355804SNPs in NRXN1 and CHRNA5 are associated to smoking and regulation of GABAergic and glutamatergic pathways. (2016 Jul)Perez-Rubio GPharmacogenomics
22291662Alternative splicing of AMPA subunits in prefrontal cortical fields of cynomolgus monkeys following chronic ethanol self-administration. (2011)Acosta GFront Psychiatry